Highlights Amplia Therapeutics Limited

Equities

ATX

AU0000023822

Market Closed - Australian S.E. Other stock markets 02:10:24 2024-07-12 am EDT			5-day change	1st Jan Change
0.062 ^AUD	+3.33%		+1.64%	-22.50%

Jul. 03	Amplia Therapeutics Completes Enrollment for Phase 2A Pancreatic Cancer Trial; Shares Up 3%	MT
May. 30	Amplia Therapeutics Limited Reports Earnings Results for the Full Year Ended March 31, 2024	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Amplia Therapeutics Completes Enrollment for Phase 2A Pancreatic Cancer Trial; Shares Up 3%	Jul. 02	MT
Amplia Therapeutics Limited Reports Earnings Results for the Full Year Ended March 31, 2024	May. 30	CI
Amplia Therapeutics Completes AU$4.27 Million Entitlement Offer; Shares Up 9%	May. 14	MT
Amplia Therapeutics to Raise AU$4.3 Million for Cancer Trials, Drug Capsule Manufacturing	Apr. 16	MT
Amplia Therapeutics Secures US FDA Clearance for Proposed Pancreatic Cancer Trial	Jan. 17	MT
Amplia Therapeutics Limited Announces FDA Clearance of it's IND for Pancreatic Cancer Trial in US	Jan. 17	CI
Amplia Therapeutics Secures South Korean Regulatory Approval for Pancreatic Cancer Trial; Shares Up 3%	Dec. 04	MT
Amplia Therapeutics Limited Reports Earnings Results for the Half Year Ended September 30, 2023	Nov. 20	CI
Amplia Therapeutics Receives AU$2.4 Million R&D Tax Rebate	23-10-18	MT
Amplia Therapeutics Limited Reports Earnings Results for the Full Year Ended March 31, 2023	23-05-30	CI
Amplia Therapeutics to Enter Research Collaboration with CSIRO; Shares Rise 7%	23-05-21	MT
Amplia Therapeutics Secures Clearance for Third Dose Cohort of Pancreatic Cancer Trial	23-04-11	MT
Amplia Therapeutics Limited Announces Completion of Enrolment of the Second Cohort of Patients in the Ongoing Phase 1b/2a ACCENT Clinical Trial in Frontline Patients with Pancreatic Cancer	23-02-27	CI
Amplia Therapeutics Limited Announces First Patient Recruited to Cohort 2 of Accent Trial in Pancreatic Cancer	23-01-31	CI
Amplia Therapeutics Limited Announces Dose Escalation Approved in ACCENT Clinical Trial of AMP945	23-01-10	CI
Amplia Therapeutics Limited Reports Earnings Results for the Half Year Ended September 30, 2022	22-11-17	CI
Amplia Therapeutics Limited Reports New Data of its Second Focal Adhesion Kinase Inhibitor AMP886 for the Treatment of Acute Myeloid Leukemia	22-10-02	CI
Amplia Therapeutics Limited Announces First Patient Recruited to ACCENT Trial in Pancreatic Cancer	22-08-01	CI
Amplia Therapeutics Changes Principal Place of Business	22-06-24	MT
Amplia Therapeutics Limited Shows AMP945 Efficacy in Model of Lung Fibrosis	22-06-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Amplia Therapeutics Limited

Equities

ATX

AU0000023822

Highlights

Filters